“The deal would help J&J add a promising therapy for cancer and move further into a hot space for drugmakers that has witnessed a rush of deals in recent months.
In November, AbbVie said it would buy ADC-developer ImmunoGen for $10.1 billion in cash. Other deals include Pfizer's $43 billion deal for Seagen and Merck's MRK.N> announcement that it would pay Daiichi Sankyo $5.5 billion to jointly develop three ADCs.”
^^ Lmao the quackcine manufacturers are making big bets on cancer treatments! LOL after it’s been proven that their products were adulterated well beyond fda’s limits with cancer-promoting SV40 dna plasmids… LMAO
“The deal would help J&J add a promising therapy for cancer and move further into a hot space for drugmakers that has witnessed a rush of deals in recent months.
In November, AbbVie said it would buy ADC-developer ImmunoGen for $10.1 billion in cash. Other deals include Pfizer's $43 billion deal for Seagen and Merck's MRK.N> announcement that it would pay Daiichi Sankyo $5.5 billion to jointly develop three ADCs.”
^^ Lmao the quackcine manufacturers are making big bets on cancer treatments! LOL after it’s been proven that their products were adulterated well beyond fda’s limits with cancer-promoting SV40 dna plasmids… LMAO